+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 18Years +
All Genders
ID07163325

Phase 1 Study of Oral EP102 Treatment in Adults with Advanced Solid Tumors to Evaluate Safety, Dosage, and Anti-Tumor Effects

Led by Epics Therapeutics · Updated on 2026-06-11

48

Participants Needed

11

Research Sites

52 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating EP102, an investigational drug, in participants with advanced solid tumors who have either no standard treatment options available or have not responded to existing therapies. This first-in-human Phase 1 study aims to determine the maximum tolerated dose MTD, safety, and how the drug behaves in the body, as well as an initial assessment of its effect on tumors. The study will help guide dosing for future research and treatment evaluations. Participants receive EP102 orally at different dose levels in a sequential, open-label design. The study focuses on identifying safe and tolerable doses, characterizing the drugs pharmacokinetic and pharmacodynamic profiles, and exploring anti-tumor activity. Treatment and assessments occur up to 21 days after the first dose, with continued evaluation until the study concludes. Throughout the trial, participants undergo evaluations to monitor safety, drug levels in the blood, and any effects on tumors. Researchers measure outcomes such as tolerability, pharmacokinetics, and tumor response. The study lasts up to the final completion date, with careful monitoring to inform the development of further studies and dosing strategies.

CONDITIONS

Brief Title

EP102 Safety and Efficacy in METTL3 Modulation in Advanced Solid Tumors

Research Team

C

Clinical Trial Liaison

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here